Celgene has decided against taking an option on Oncomed’s cancer drug navicixizumab, sending the California biotech’s shares into freefall. Following the announcement Oncomed’s value fell by nearly 14% on the Nasdaq following the news that Celgene...
Original Article: Celgene passes on OncoMed cancer drug, biotech's shares tank